Novel immunological tools for efficient diagnosis and treatment of emerging infections are urgently required. Advances in the diagnostic and vaccine development fields are continuously progressing, with Reverse Vaccinology and Structural
Introduction
Together with improved nutrition and hygiene, efficient disease diagnosis and vaccination are medicine landmarks that have promoted major improvements in human health and longevity [1, 2] . In diagnostics, significant progress has been observed in the development of disease-specific probes, in the types of materials used for their presentation, and in the sensitivity of the associated detection methods. It is now possible to design new (bio)molecules that recognize specific biomarkers (see Glossary) , such as antibodies (Abs) elicited in response to infection, and improve our understanding of the molecular mechanisms underlying the immune response [3] . The impacts of such advances are particularly visible in fields where diagnosis typically required invasive techniques or complex scanning machineries. In parallel, vaccines offer great potential to tackle infectious diseases caused by emerging pathogens, multi-drug resistant bacteria, parasites and viruses, and lately in the treatment of cancer and HPV, or HIV and even Ebola [4] [5] [6] [7] . Vaccines help prevent and/or cure diseases by activating the immune system against (future) attacks. A fundamental step in the delivery of protective vaccines has been, and is, the development of new approaches to the discovery and engineering of protein antigens (Ags) capable of eliciting apt immune responses.
Epitopes, the specific molecular regions of an antigen that are recognized in the immune response, may represent ideal immunoreagents that can be conjugated to other known immunogens (proteins and otherwise), or presented in combination with other epitopes on chemical or biological scaffolds, increasing their applicative potential as diagnostics and vaccine components [8] . A holistic approach, integrating both diagnostic probe and vaccine candidate design, is summarized in Figure 1 .
Here, we review novel avenues and perspectives for Ag/epitope discovery and engineering in immunodiagnostics and vaccinology, based on the combination of protein 3D structures, in silico analyses and design strategies. We discuss specific applicative examples and highlight their implications for engineering synthetic molecules with improved immunological properties for diagnostic and/or therapeutic applications. Notably, although much of the research discussed originated from the need to combat specific infectious diseases, the scope of the approaches we present is vast, and in principle transferable to any disease-related Ag of known 3D structure.
Bioinformatics antigen selection: the Reverse Vaccinology revolution
In contrast to classical methods based on attenuated or killed pathogen particles to prompt the host immune response, modern vaccinology can rely on Ag discovery via bioinformatics; Reverse Vaccinology (RV; Box 1) explores pathogen genomes to identify Ags for downstream in vivo validation as vaccine candidates [9, 10] . Potential Ag genes are picked out from the bacterial genome via bioinformatic mining for specific sequence motifs, such as those encoding for outer membrane proteins, and then produced in an appropriate expression system (e.g. Escherichia coli) for testing. The extension of RV to explore multiple related pathogenic genomes, so-called Pan-genomic RV (PRV), can support the discovery of candidate Ags that cross-protect against diverse bacterial strains. The impact of RV has been exemplified by the identification of four protective Ags that formulate Bexsero R , the first vaccine targeting Neisseria meningitidis serotype B infections [11] .
Since bioinformatics analyses may yield large numbers of candidates, to reduce the number of proteins to be expressed-purified for in vivo phases, further methodological developments have been proposed, taking into account recurring structural/functional features (protective signatures) of known protective Ags, in order to better select bactericidal molecules [12] . When applied to Staphylococcus aureus and Group B Streptococcus, such 'protectome' analyses identified two previously unknown Ags, and 'rediscovered' known ones [12] .
The role of structural studies in Ag engineering
Ag discovery can be efficiently supported by structure-based design concepts.
In this context, Structural Vaccinology (SV) (see Glossary and Box 1), whereby 3D information is used to reveal the determinants of Ag stability and conformational dynamics underlying molecular recognition by the immune system, has recently emerged as a new driving force in immunology. Advances in X-ray crystallography,
Nuclear Magnetic Resonance (NMR) and single particle Cryo-Electron
Microscopy (Cryo-EM), are in fact facilitating the study of challenging Ags, particularly when applied to Ag and Ag-Ab complex structures and interaction studies [9, 13, 14] .
Coupled to in vitro epitope mapping data and computer-aided Ag engineering, 3D structural knowledge can pinpoint the location and physico-chemical properties of the epitopes that are ultimately responsible for triggering B-cell and/or T-cell mediated immune responses [15] (Figure 1 ). Structural knowledge on epitopes can also drive the design of peptide-based mimics (or libraries), epitope-containing protein domains, or completely new Ags that on one hand are reactive versus disease biomarkers, and on the other can elicit bacteria-neutralizing responses [9, 13] .
Successful achievements of SV include applications to the Respiratory Syncytial
Virus fusion protein Ag and the Factor H binding protein (FHbp) Ag from MenB, respectively [11, 16] .
To progress along such promising avenues, we must address fundamental questions: 1) can we formulate general principles that allow immune-reactive and non-reactive epitope substructures to be distinguished?; 2) is it possible to design peptide-based epitope mimics (to be presented in multiplex or multivalent formats) as diagnostic probes that detect specific biomarkers?; 3) is it possible to translate epitope knowledge into the design of 'super-Ags' presenting multiple T-/B-cell epitopes that induce better protection compared to their single epitope counterparts? In fact, epitope-based vaccines can offer several advantages: they may be more readily produced on an industrial scale, are easily presented through diverse delivery vessels and adjuvants, and may be engineered to improve their antigenicity. In diagnostic applications, the possibility of displaying multiple reactive epitopes from one pathogen can facilitate the transition towards high-throughput approaches.
Epitope discovery and design
The first prerequisite to meet the above challenges is our ability to predict and locate epitope regions as privileged Ag-substructures capable of selectively engaging molecules of the immune system.
a) Epitope predictors based on general molecular properties
Computational methods for epitope prediction are playing increasingly important roles, thanks to continuous technological advances in computing. Moreover, a number of databases such as the Immune Epitope DataBase (www.iedb.org) [17] , AntiJen [18] , and the international ImMunoGeneTics (IMGT) [19] have been devised to collect experimental epitope sequence data, and to provide tools for the discovery of new epitopes, whilst providing information on those already mapped.
Although the precise criteria that determine immunogenic properties remain elusive, a number of molecular features shared by effective epitopes have been observed. Examples include localized physico-chemical properties, such as hydrophobicity, solvent-exposure, flexibility or lack of sequence conservation. Such observations led to the development of several computational algorithms. Notable examples of servers that predict B-cell epitopes through the combination of different molecular properties into a single predictor include ElliPro [20] (http://tools.immuneepitope.org/ellipro/) and SEPPA [21] (http://lifecenter.sgst.cn/seppa/).
b) Sequence-based epitope predictors
Due to the linear nature of T-cell epitopes, in silico sequence-based methods that predict both MHC class I and, to a lesser-extent, MHC class II molecule presentation, can be highly accurate. Recent examples include MULTIPRED [22] , TEPITOPE (Human Leukocyte Antigen (HLA) class I) [23] , and ProPred [24] (HLA class II predictor). It must be underlined that these approaches identify epitopes based on their predicted HLA binding affinities, and no information on their potential immunogenicity is revealed.
Predictions of B-cell epitopes, targeted by Abs in the initial stages of the immune response, are more challenging, since 3D structure information is typically required. Sequence-based methods were previously limited to the prediction of linear epitopes, however tools for the prediction of conformational epitopes, which represent a large subset of all B-cell epitopes, including many capable of inducing bactericidal responses [25] , have recently emerged thanks to machine learning approaches [26, 27] 
c) Structure-based epitope predictors
As the interplay between sequence and conformational properties underpins [28] analyzes the dynamic and energetic properties of Ag structures, and identifies contiguous surface-located residues that build low intensity interaction networks with designated core protein regions [29] . Such substructures are not required for global stabilization of the Ag, may tolerate mutations and may be highly dynamic, all hallmarks of typical B-cell epitopes.
MLCE, whose predictions reach promising accuracy (AUC 0.71), has been tested against Ags from diverse bacterial pathogens. Successful application to Chlamydia and Burkholderia pseudomallei Ags led to the identification of epitopes with both therapeutic and diagnostic implications [30] [31] [32] [33] . MLCE/BEPPE can also be combined with energy domain decomposition methods to fragment proteins into sub-domains [34] prior to epitope predictions, revealing 'hidden epitopes' that may evade identification but be potentially interesting in generating immune responses [35] ( Figure 2 ). Importantly, these energy-based strategies proved successful for identifying conformational epitopes. This task is now becoming increasingly feasible thanks to the soaring numbers of Ag and Ag-Ab 3D complex structures in the Protein Data Bank (http://www.rcsb.org).
The accuracy of the fore-mentioned methods may be further enhanced by combining them with approaches that focus on diverse physico-chemical properties.
As for protein-protein interactions in general, Ab-Ag binding involves displacement of water molecules bound at the interaction interfaces: the Electrostatic Desolvation Profiles (EDP) method scans the protein surface, looking for solvent-accessible clefts and calculates the theoretical desolvation penalty for each site, upon binding of a protein partner, selecting those where water displacement is favored [36] .
Synthetic epitope mimics: structure-activity relationships.
Information on the immunoreactive potential of epitopes coupled to the synthetic accessibility of peptides opens the way to chemical interventions aimed to modulate their structures and to assess how specific conformational ensembles affect Ab-recognition. One approach is to constrain peptides into the desired conformation by means of covalent modifications, such as stapling and macrocyclization [37] [38] [39] .
Ideally, a stapling strategy may be a versatile tool to produce synthetic epitopes that closely mimic the conformational space of their native counterparts, such as loops and turns. For instance, the correct spacing between extremities of a loop can be achieved through a suitable macrocyclization process, or through the inclusion of PEG moieties mimicking the spatial distance between them [35] .
This rationale was applied to a computationally-predicted epitope (Pal3) from the pathogenic bacterium Burkholderia pseudomallei ( Figure 3 ) that was found to be strongly immunoreactive [40] . In the cognate Ag, the epitope adopts an α-helical conformation; when synthesized as a free peptide, in contrast to the full-length protein, the epitope mimic could clearly discriminate between melioidosis patient serogroups, and elicited bactericidal Abs. In the free peptide form, however, the epitope was unable to retain its α-helical conformation and, accordingly, exhibited poor stability in plasma. A 1,4-disubstituted-1,2,3-triazole staple was introduced to block the -helical fold of Pal3, which improved both its half-life in human plasma and patient IgG recognition. In contrast, the Abs generated against the stapled peptide proved significantly less bactericidal than those elicited against the unconstrained epitope [40] . This observation was reconciled considering that, when housed in the recombinant Ag, the epitope region may undergo local folding-unfolding reactions that present different conformations to the polyclonal pools of generated Abs.
Blocking a single conformation in the stapled synthetic epitope may thus give rise to a limited pool of Abs that recognize fewer epitope conformations. Such restrictions were not observed for the unstapled version of Pal3. In contrast, conformational preorganization of the synthetic epitope was found to improve its diagnostic performance, most likely by increasing affinity for specific Abs, translating into better readable signals. While the Pal3 case was one of the first reports of a stapling strategy applied to a peptide with diagnostic applications, these results suggest that the balance between conformational freedom and immunogenicity deserve more extended investigations [30, 40] .
An additional notable example of epitope stapling involves the SAH-MPER linear epitope from the HIV gp41 protein. The constrained epitope was remarkably resistant to proteolysis, and was able to recapitulate its native antigenic properties by binding neutralizing Abs with high affinity [39] . The stapling technique used in this case involved the direct linkage of two carbon atoms within the epitope.
Multi-presentation of designed epitopes
Peptides mimicking Ab-recognition motifs of different Ags are ideal tools for multiplex approaches, whereby multiple epitopes can be presented simultaneously, both for detection of (multiple) biomarkers and for the induction of improved immune Another case reported the detection of Burkholderia cepacia complex infections from sera of Cystic Fibrosis (CF) patients using a peptide-based microarray platform [32] . In this case, peptide-mimics of predicted Ag-Ab binding interfaces were identified and chemically optimized for click-chemistry controlled orientation on the microarray surface. The resulting platform, displaying multiple Burkholderiarelated epitopes was able to correctly diagnose infected individuals even in the face of superinfections caused by other prevalent CF pathogens [32] . The time and cost for the analysis were contained, and the results demonstrated that a peptide microarray approach may elucidate Burkholderia sp. infection even at the subtype level.
Multi-presentation: from nanoparticles to structure-based epitope grafting
One of the most exciting perspectives for computational epitope engineering is the development of new vaccines, and of novel epitope delivery vessels as agents promoting the immune response. A possible multiplex approach based on nanocarriers is illustrated in Figure I , Box 3
These carriers can be mainly of two kinds: inorganic (e.g. gold) nanoparticles (AuNPs) functionalized with antigenic epitopes, and vesicular nanoparticles, composed of vesicles or liposomes, capable of carrying the Ags on their surface or inside the bilayer. Products based liposomal carriers are already commercial, such as Inflexal® V against influenza and Epaxal® against Hepatitis A [45] . One of the advantages of this technology is that lipid composition can be adjusted to meet desired properties, including size to accommodate the cargo, charge (charged liposomes are able to enhance the innate immune response stimulation [46] , fluidity, or the inclusion of immunostimulatory lipids such as CAF01 [47] orgalactosylceramide [48] .
Concerning epitope presentation and delivery, liposomes may accommodate different epitopes encapsulated in the aqueous core or displayed at the surface.
Epitope attachment can be mediated by covalent-or hydrophobic-anchors adsorbed through the lipid layer. Alternatively, the epitope may be designed and synthesized to include a transmembrane helix to promote liposome [49] attachment. Such versatility allows optimal display of synthetic epitopes: for instance, they may be presented directly to immature B-cells adsorbed or linked at the surface of the nanocarriers. On the other hand, T-cell epitopes may be encapsulated within the bilayer, and optimized in size and composition to be internalized by Ag-presenting cells, where the nanovesicles can release their cargo. It is known that different vesicles may promote uptake by different cellular types, so to favor MHC-I or MHC-II presentation [50] [51] [52] .
One such approach was tested with good results by Irvine and coworkers, who Evolving these technologies for vaccine purposes is a hot research topic [52] .
Even if a protocol that gives rise to neutralizing protection has yet to be demonstrated, some encouraging results have been achieved [54] . Such studies hint at the possibility of using nanoparticles not only as viable carriers, but also to promote a boost in immunogenicity compared to the use of the individual Ags, a common plus of nanocarriers. This aspect introduces further potential for rational engineering of the immunological response. Liposomes and nanoparticles can be in fact prepared to display a large diversity of epitopes, recapitulating the immunogenic determinants of many Ags into a single component. Also, the carriers can be optimized for specific tasks: diffusion, stability, stimulation of one specific branch of the adaptive immune response, act as cytokine carriers, act as adjuvants, or they can be designed to carry over many tasks at the same time. Compared to the typical subunit vaccine, the increase in complexity is high but the technological gain and the possibilities that they open are highly exciting.
Chimeras
Among the strategies that employ the rational design of Ags and epitopes, we consider the case of "chimeras" as a particularly interesting one [16] (Figure 4 ). One
Ag can be characterized for sequence similarity across multiple pathogenic variants; then, assisted by 3D structural data, it is possible to assess the differences that define the variant-specific neutralizing epitopes. A series of mutations that encompass the regions of variability as well as specificity, can lead to a single recombinant Ag able to trigger a neutralizing effect in multiple strains, as successfully accomplished for factor H binding protein (fHbp) from Neisseria meningitidis group B (MenB) [55] . In this case, a broadly reactive Ag was requested in order to induce protection against all major MenB strains and, along with the other Ags in the formulation, to provide an effective vaccine. The objective was met by screening many different variants and mutations; however, this process may benefit from additional knowledge on the structural features of Ag-Ab recognition (e.g. Ags co-crystallized with FABs of selective Abs). In this regard, computational studies integrating sequence conservation across variants (bioinformatics) and Ag-Ab binding modeling and optimization (computational chemistry) or crystal structures, may help focus on a smaller set of "hotspot" residues within the epitope, thus reducing residue permutations to those that are more prevalent across the strains of interest, eventually minimizing the number of screened mutations.
Epitope Grafting
Computational design of proteins to host foreign functional motifs can give rise to Ags with new functionalities or diverse immunological properties. This strategy, termed 'epitope grafting', can be used to selectively stabilize suitable conformations of epitopes for immune presentation or to address antigenic variability of diverse pathogenic species ( Figure 5, Box 4 ). Simultaneous presentation of multiple epitopes on the same scaffold is known to induce stronger and more durable immune response. For some pathogens, in particular of intracellular nature, joint cellmediated and humoral immune responses are required for a sterilizing vaccine. It has been shown that immunization with chronic and acute phase Mycobacterium tuberculosis Ags on the same polypeptide chain, induces a better protective response in comparison to administering both Ags separately [56] . As an alternative to expressing the full-length forms of multi-Ags on the same polypeptide chain, epitopegrafting strategies could be adopted to combine both T-cell and B-cell epitopes within the same protein scaffold.
For successful epitope grafting, a main prerequisite is the availability of a protein scaffold that presents a 3D structure reflecting or compatible with that of the target Ab recognition motif to be transplanted. The field is evolving rapidly, but it has yet to reach its full potential. Using the Fold From Loops (FFL) method that designs scaffold proteins hosting new functional motifs, a neutralizing epitope from human respiratory syncytial virus (RSV) glycoprotein was grafted onto an unrelated protein scaffold, which elicited neutralizing Abs [57] . A recent report describing an automated tool for the implantation of immunogenic epitopes onto a given scaffold, named SAGE (Strategy for Alignment and Grafting of Epitopes), was published. The method considers both sequence and structure conservation between target epitopes and scaffolds, and is fully applicable to any protein from any pathogen for which the epitope location within the Ag 3D structure is known [58] .
Concluding Remarks
Health challenges posed by globalization underline the growing request for Health challenges must also be faced through adequate diagnostic capabilities.
Due to extensive migration of world populations, pathogen diffusion between continents is increasing, calling for rapid, robust and practically facile diagnostic tests for use in hospitals and refugee camps/centers to diagnose, and contain, emerging infections. In this context, protein antigens/epitopes can be used to detect the presence and phase of pathogen infection by monitoring their recognition by cognate serum antibodies. The predictive capabilities acquired through the application of fundamental principles of protein structure recognition are therefore translating into new bio-reagents for the assembly of diagnostic tools based on microarray display technologies. Here, engineering of antigens/epitopes in a multiplex context is the most promising approach, given the possibility of multiple diagnostic queries on the same support, which can aptly translate in an efficient profiling of the disease and disease state, thus favoring patient stratification and therapeutic decision-making.
As in other branches of life sciences, genomic data and fundamental information on protein structure and dynamics are fostering the development of translational science. It is expected that vaccines and immunodiagnostics will soon rely on faster discovery and production methods, and on the broad distribution of safe-stable bio-reagents.
Major Histocompatibility Complex: MHC, Protein complex present on the cell-
surface in all vertebrates that helps the immune system recognize foreign substances by binding to antigens and presenting them to T-cells.
Multiplex: the presentation of multiple biomarkers on a suitable vessel.
Neutralizing Abs: Antibodies that eradicate a pathogen from the body.
Nuclear Magnetic Resonance: Spectroscopy-based analytical technique used to determine 3D structures by exploiting the magnetic properties of atomic nuclei arranged within a (macro)molecule.
Peptoid: poly-N-substituted glycine residues that are protease-resistant peptide mimics.
Reverse Vaccinology: a bioinformatics-based approach to Ag identification, starting from pathogen genome sequence data.
Structural Vaccinology: the use of 3D structure information to guide specific engineering of antigens endowed with improved biochemical and/or immunological properties.
T-cell:
Front-runner in cell-mediated immunity. There are several types of T-cell (or T-lymphocyte) that trigger and facilitate diverse types of immune response.
X-ray crystallography:
A biophysical technique that reveals the 3D arrangement of atoms in a crystallized (macro)molecule, based on the application of X-rays whose wavelength approximately matches the typical dimensions of atomic level features, which are therefore resolved in the electron density maps.
Text Boxes

BOX 1: Reverse Vaccinology and Structural Vaccinology in Vaccine
Development
Since the genomic advent in 2000, which led to increasing pathogen genome sequence information, bioinformatics-based methods for antigen selection (termed Reverse Vaccinology, RV) have taken over laborious and time consuming conventional approaches that require pathogen cultivation [10, 59] . RV methods predict surface-exposed or secreted proteins that are the first point of contact for immune system molecules as potential antigens, based on the presence of signal peptides and/or other sequence motifs that imply cell surface location, e.g.
transmembrane regions, sortase recognition motifs, and sequence conservation with known antigens. When multiple pathogen species genomes are available, RV can be extended to identify proteins pertaining to the pan-genome, shared by all species, whose common antigens could potentially protect against more than one species. In silico selected candidate antigens are subsequently validated for their effective immunological properties in vitro and in in vivo animal models.
Since protein antigen immunogenicity is directly determined by overall threedimensional fold, conformations and related dynamics, unsurprisingly, structurebased antigen design followed closely on the heels of RV (originating Structural Vaccinology, SV). Based on 3D structure information, structural modifications such as the introduction of disulfide bonds can be strategically introduced to block typically transient conformations of neutralizing epitopes or antigens, as exemplified by the Respiratory Syncytial Virus (RSV) glycoprotein F antigen [15] . Alternatively, SV can be used to design epitope-containing domains that may be easily produced in recombinant form for industrial-scale production, as an alternative to the full-length antigen. Moreover, mutations can be introduced in epitope regions to account for interspecies sequence variability to generate crossprotective antigens. In short, SV can be used to specifically tailor protein antigens that can be rapidly produced for immediate testing of their biochemical and/or immunological properties. The maturity of the technique has been proven by the many published clinical applications and by the several commercial providers offering support and services.
BOX 3: Nanocarriers for epitopes
Chemistry at the nanoscale is providing useful approaches to address biologically-relevant problems (Figure I ). Particles and molecular machines of nm dimensions are being increasingly and more extensively used as drug-delivery tools for targeted therapeutics, for instance in cancer applications. In the context of vaccine delivery systems, nanotechnology can provide new solutions for the development of safe and effective products. In principle, by linking several different antigens (even of different chemical origin, e.g. proteins and carbohydrates) on the same carrier, it is possible to create highly reactive systems that may provide strong and durable protection: several studies have proven this potential, by encapsulating antigens to improve their stability or to promote presentation by displaying antigens on the nanoparticle surface. In this context, gold nanoparticles (AuNPs) have generated huge interest thanks to their biocompatibility, low toxicity, imaging properties and the ability to release antigens at specific sites through targeting [62] . In the case of peptide-based epitope mimics, the facile approaches to link peptides to the surfaces based on sulfur-gold chemical reactivity allows for the versatile inclusion of structurally diverse sequences.
In the nanoparticle field, Outer Membrane Vesicles (OMVs) represent an innovative technology that allows several Ags (of e.g. bacterial or cancer origin)
to be expressed and displayed on the vesicle surface. OMVs are heterogenous spheroid particles (10-300 nm in diameter) generated through the budding out of the bacterial outer membrane in Gram-Negative bacteria. OMVs purified from several pathogens proved to induce protective immune responses against the pathogens they derive from. Importantly, anti-Neisseria OMV-based vaccines are already available for human use [63] [64] [65] . Such remarkable protection can be linked to the fact that: they carry surface-associated protective antigens; they are readily phagocytosed by antigen-presenting cells, favoring presentation of antigen-derived peptides; and OMVs carry pathogen-associated-molecular patterns which target pathogen recognition receptors stimulating both innate adaptive immune responses. In the context of rational vaccine design, a key feature of OMVs is the possibility to manipulate their protein content and surface display by genetic engineering, directing protein expression to the outer membrane of the OMV-producing strain. This would clearly favor to development of highly effective multi-valent vaccines. Finally, such nanoparticles are gaining increasing attention for their inbuilt adjuvant capabilities. All these properties make nanoscale-type materials ideal reagents to be combined with structurebased, rational antigen and epitope design.
BOX 4: Epitope grafting approaches for multiple epitope presentation
Most infections are characterized by diverse phases, for example acute and chronic phases, which require activation of both humoral and cell-mediated immune responses; thus, both B-and T-cell epitopes are vital components of protective vaccine formulations. Simultaneous, rather than consecutive presentation of epitopes is known to trigger stronger and more durable immune responses, therefore multiple epitopes should ideally be presented on the same polypeptide chain or via the same chemical scaffold. With regards to proteinbased scaffolds, atomic level structure data and computational biology design methods can be used to remove an epitope from its host antigen and to transplant it onto a conformationally-apt region of an entirely different recipient protein ( Figure 5 ). This can endow the grafted epitope with new and improved immunological properties. For example, in its parental antigen, a neutralizing epitope may be masked by other less important, yet conformationally dominant epitopes; transplanting it to a new scaffold may improve its accessibility to the molecules governing the immune response. When the protein scaffold itself is an antigen, epitope grafting can be used to present multiple epitopes, e.g. T-and Bcell epitopes to trigger both the innate and humoral immune responses. In this case, attention must be made to ensure that the grafted epitope does not mask the host scaffold epitopes.
Figure Captions
Figure 1 -An overview of the different structure-based computational methods that are described in this review, starting from selection of conformational or linear epitopes originating, e.g.,from a viral capsid or from a protein antigen. -Epitopes recognized within a given antigen can be transplanted onto a different antigen, to boost its immunogenic properties, provided that the conformational context in which the new epitope is to be grafted is compatible with its original structure.
Figure I, Box 3 -
A schematic representation of the potential offered by decoration of nanoparticle or vesicles with peptide epitopes identified through the computational methods here described.
